A coalition of tech and life sciences leaders and AI companies called for mandatory screening and recordkeeping for synthetic nucleic acid orders, arguing that current safeguards are insufficient as capabilities scale. The effort, supported by executives across organizations including Google DeepMind, OpenAI, Anthropic, Meta, Microsoft, Twist Bioscience, and Ansa Biotechnologies, urges U.S. lawmakers to codify controls for orders of synthetic DNA and associated equipment. Separately, arXiv announced a penalty policy targeting “AI slop” submissions with evidence of fabricated or unreliable content, reflecting growing attention to research integrity at scale. While the arXiv move targets literature quality, the synthetic DNA letter targets upstream biosupply-chain risk. Together, the developments show how biotech-adjacent policy and platform governance are being tightened across both discovery ecosystems and biosecurity supply chains.